Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
All content for Evaluating Biopharma is the property of Evaluating Biopharma and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
Episode: 9 - Gene Therapy Analytics: Identifying and Overcoming CMC Challenges in Gene Therapy
Evaluating Biopharma
24 minutes
2 years ago
Episode: 9 - Gene Therapy Analytics: Identifying and Overcoming CMC Challenges in Gene Therapy
In this episode of Evaluating Biopharma, Ben Locwin, Vice President of Project Solutions at Black Diamond Networks, speaks with Susan D'Costa, Chief Technology Officer at Alcyone Therapeutics, who shares her experiences and provides advice on how your company can identify and overcome CMC challenges in gene therapy, including: understanding and monitoring DNA constructs, identifying starting material challenges, prioritizing potency assays, and the impact of viral vector delivery and developm...
Evaluating Biopharma
Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
